Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
OA01 - Real World Data to Guide Our Daily Needs
- 10:45 - 11:45
- 8/07/2022
- Location: Strauss 3
- Not for CME Credit
- Type: Oral
- Track: Global Health, Health Services Research, and Health Economics
- Moderators:Gyula Ostoros, Oscar Arrieta
-
+
OA01.05 - Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study
11:07 - 11:17 | Presenter: Ruth Pamela Norris
- Abstract
Loading...
-
+
OA02 - From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment
- 12:00 - 13:00
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Locally Advanced Non-small Cell Lung Cancer
- Moderators:Isabelle Opitz, Luis Paz-Ares
-
+
Session Moderator
12:00 - 12:00 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
Session Moderator
12:00 - 12:00 | Presenter: Isabelle Opitz
- Abstract
Loading... -
+
OA02.01 - Session Introduction
12:00 - 12:01 | Presenter: Isabelle Opitz
- Abstract
Loading... -
+
OA02.02 - Session Introduction
12:01 - 12:02 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
OA02.03 - Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
12:02 - 12:12 | Presenter: Marta Casarrubios
- Abstract
Loading... -
+
OA02.04 - Multimodal Management of T4 N2 Non-small-cell Lung Cancer with Additional Ipsilateral Pulmonary Nodules
12:12 - 12:22 | Presenter: Arvind Kumar
- Abstract
Loading... -
+
OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
12:22 - 12:32 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
OA02.06 - Discussant
12:32 - 12:42 | Presenter: Linda Martin
- Abstract
Loading... -
+
OA02.07 - Live Q&A
12:42 - 13:00
- Abstract
Loading...
-
+
OA03 - Molecular Targeted Treatments
- 14:30 - 15:40
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Andrew Ciupek, David R. Gandara
-
+
OA03.03 - Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors
14:32 - 14:42 | Presenter: Gerald Falchook
- Abstract
Loading... -
+
OA03.04 - Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
14:42 - 14:52 | Presenter: Adrian Sacher
- Abstract
Loading... -
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Presenter: Michael Thomas
- Abstract
Loading... -
+
OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
15:02 - 15:12 | Presenter: Bob T. Li
- Abstract
Loading...
-
+
OA07 - Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?
- 11:00 - 12:00
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
- Moderators:Lubos Petruzelka, Pilar Garrido
-
+
Session Moderator
11:22 - 11:32 | Presenter: Lubos Petruzelka
- Abstract
Loading... -
+
Session Moderator
11:22 - 11:32 | Presenter: Pilar Garrido
- Abstract
Loading... -
+
OA07.01 - Session Introduction
11:00 - 11:01 | Presenter: Lubos Petruzelka
- Abstract
Loading... -
+
OA07.02 - Session Introduction
11:01 - 11:02 | Presenter: Pilar Garrido
- Abstract
Loading... -
+
OA07.03 - Association Between Genetic Variation in the ATP-binding Cassette Transporter ABCC10 and nab-PTX Treatment in Japanese Cohort
11:02 - 11:12 | Presenter: Minoru Horiuchi
- Abstract
Loading... -
+
OA07.04 - Overall Survival in Patients With Advanced NSCLC Receiving Taxane-Containing Regimen After Exposure to Immunotherapy and Platinum-Doublet
11:12 - 11:22 | Presenter: Stephen V. Liu
- Abstract
Loading... -
+
OA07.05 - Gemcitabine Plus Platinum Chemotherapy Re-challenge in Metastatic Pulmonary Lymphoepithelioma-like Carcinoma
11:22 - 11:32 | Presenter: Gavin Tin Chun Cheung
- Abstract
Loading... -
+
OA07.06 - Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
11:32 - 11:42 | Presenter: Edouard Auclin
- Abstract
Loading... -
+
OA07.07 - Discussant
11:42 - 11:52 | Presenter: Navneet Singh
- Abstract
Loading... -
+
OA07.08 - Live Q&A
11:52 - 12:00
- Abstract
Loading...
-
+
OA09 - Precision Immunotherapy via Modulation of the Tumor Microenvironment
- 14:45 - 15:45
- 8/08/2022
- Location: Lehar 1
- Not for CME Credit
- Type: Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Kurt Alex Schalper, Umberto Malapelle
-
+
OA09.05 - Neoadjuvant IL-15-PDL1 Antibody Promotes T cell Memory and Decreases Metastatic Recurrence in Resectable NSCLC
15:07 - 15:17 | Presenter: Jonathan Villena-Vargas
- Abstract
Loading...
-
+
OA11 - Optimal Patient Selection for Local Therapy in Stage IV NSCLC
- 16:00 - 17:00
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
- Moderators:Pablo Munoz-Schuffenegger, Mariana Brandao
-
+
Session Moderator
16:12 - 16:22 | Presenter: Pablo Munoz-Schuffenegger
- Abstract
Loading... -
+
Session Moderator
16:12 - 16:22 | Presenter: Mariana Brandao
- Abstract
Loading... -
+
OA11.01 - Session Introduction
16:00 - 16:01 | Presenter: Pablo Munoz-Schuffenegger
- Abstract
Loading... -
+
OA11.02 - Session Introduction
16:01 - 16:02 | Presenter: Mariana Brandao
- Abstract
Loading... -
+
OA11.03 - Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis
16:02 - 16:12 | Presenter: Peter Lee Zhan
- Abstract
Loading... -
+
OA11.04 - The Factors Associated With Reduced Risk of Progression in Patients With Oligometastatic NSCLC Treated With Local Ablative Radiotherapy
16:12 - 16:22 | Presenter: Gowoon Yang
- Abstract
Loading... -
+
OA11.05 - Treatment Strategies Based on Different Oligoprogressive Patterns after Immunotherapy Resistance in Advanced NSCLC
16:22 - 16:32 | Presenter: Shun Lu
- Abstract
Loading... -
+
OA11.06 - Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
16:32 - 16:42 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
OA11.07 - Discussant
16:42 - 16:52 | Presenter: Digambar Behera
- Abstract
Loading... -
+
OA11.08 - Live Q&A
16:52 - 17:00
- Abstract
Loading...
-
+
OA13 - Evolving Epidemiology of Lung Cancer Beyond Tobacco
- 10:45 - 11:45
- 8/09/2022
- Location: Hall C8
- Not for CME Credit
- Type: Oral
- Track: Epidemiology
- Moderators:Matthew T Warkentin, Hilary A Robbins
-
+
OA13.04 - Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
10:57 - 11:07 | Presenter: Miguel Garcia Pardo
- Abstract
Loading...
-
+
OA14 - New Techniques to Improve Outcome in Early Stage NSCLC Patients Treated with Surgery or Radiotherapy
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C8
- Not for CME Credit
- Type: Oral
- Track: Early Stage Non-small Cell Lung Cancer
- Moderators:Paul Van Schil, Fabio Moraes
-
+
Session Moderator
12:00 - 12:00 | Presenter: Paul Van Schil
- Abstract
Loading... -
+
Session Moderator
12:00 - 12:00 | Presenter: Fabio Moraes
- Abstract
Loading... -
+
OA14.01 - Session Introduction
12:00 - 12:01 | Presenter: Paul Van Schil
- Abstract
Loading... -
+
OA14.02 - Session Introduction
12:01 - 12:02 | Presenter: Fabio Moraes
- Abstract
Loading... -
+
OA14.04 - Chest Wall Toxicity after Individualized Stereotactic Ablative Radiotherapy for Lung Tumors
12:02 - 12:12 | Presenter: Brianna Lau
- Abstract
Loading... -
+
OA14.05 - Intraoperative Molecular Imaging Guided Resection of CEACAM5+ Lung Tumors: First In-Human SGM-101 Lung Cancer Surgical Trial
12:12 - 12:22 | Presenter: Feredun Azari
- Abstract
Loading... -
+
OA14.06 - T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing
12:22 - 12:32 | Presenter: Filiz Oezkan
- Abstract
Loading... -
+
OA14.07 - Discussant
12:32 - 12:42 | Presenter: Brendon Stiles
- Abstract
Loading... -
+
OA14.08 - Live Q&A
12:42 - 13:00
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
Session Moderator
14:32 - 00:00 | Presenter: Pilar Garrido
- Abstract
Loading... -
+
Session Moderator
14:32 - 00:00 | Presenter: António Araújo
- Abstract
Loading... -
+
OA15.01 - Session Introduction
14:30 - 14:31 | Presenter: Pilar Garrido
- Abstract
Loading... -
+
OA15.02 - Session Introduction
14:31 - 14:32 | Presenter: António Araújo
- Abstract
Loading... -
+
OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
14:32 - 14:42 | Presenter: Martin Reck
- Abstract
Loading... -
+
OA15.04 - Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
14:42 - 14:52 | Presenter: Solange Peters
- Abstract
Loading... -
+
OA15.05 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy
14:52 - 15:02 | Presenter: Benjamin Besse
- Abstract
Loading... -
+
OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
15:02 - 15:12 | Presenter: Delvys Rodriguez-Abreu
- Abstract
Loading... -
+
OA15.07 - Discussant
15:12 - 15:22 | Presenter: Puey Ling Chia
- Abstract
Loading... -
+
OA15.08 - Live Q&A
15:22 - 15:30
- Abstract
Loading...